Tag : INVASIVE DISEASE-FREE SURVIVAL

CONFERENCE UPDATE

Adjuvant abemaciclib + ET reduces risk of death in HR+, HER2-, high-risk early breast cancer: Primary OS results from the monarchE trial
The monarchE trial reveals that adjuvant abemaciclib combined with endocrine therapy significantly enhances overall survival (OS) and invasive disease-free survival in patients with high-risk, hormone receptor-positive, HER2-negative early breast cancer, establishing this regimen as a new standard of care.

Professor Stephen Johnston

The Royal Marsden, NHS Foundation Trust, London, United Kingdom